Novo Nordisk A/S (NYSE:NVO) Shares Sold by Fiduciary Trust Co

Fiduciary Trust Co trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 198,679 shares of the company’s stock after selling 2,595 shares during the quarter. Fiduciary Trust Co’s holdings in Novo Nordisk A/S were worth $23,657,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. International Assets Investment Management LLC raised its stake in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC grew its holdings in shares of Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth about $98,765,000. Marshall Wace LLP increased its position in shares of Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at about $41,646,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Stock Down 0.0 %

Shares of NYSE:NVO opened at $106.12 on Thursday. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm’s 50-day simple moving average is $113.80 and its 200-day simple moving average is $128.33. The company has a market cap of $476.22 billion, a price-to-earnings ratio of 34.34, a PEG ratio of 1.35 and a beta of 0.42.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.